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Summary 
Background: Nitric oxide (NO) is oxidative stress biomarker
which is regarded as one of the key determinants of energy
metabolism and vascular tone. Considering the controver-
sial reports on the association between nitric oxide prod-
ucts (NOx) and metabolic syndrome (MetS), the aim of the
current study was to examine that potential relationship.
Additionally, we aimed to evaluate a broad spectrum of
other oxidative stress biomarkers [i.e., malondialdehyde
(MDA), advanced oxidation protein products (AOPP), xan-
thine oxidoreductase (XOD), xanthine oxidase (XO) xan-
thine dehydrogenase (XDH)] in relation with MetS.
Methods: A total of 109 volunteers (46.8% of them with
MetS) were included in this cross-sectional study. Bio -
hemical and anthropometric parameters, as well as blood
pressure, were obtained. The MetS was diagnosed accord-
ing to the International Diabetes Federation criteria. 
Results: Multivariate logistic regression analysis showed
that XOD (OR=1.011; 95% CI 1.002–1.019; p=0.016),
XO (OR=1.014; 95% CI 1.003–1.026; p=0.016), MDA
(OR=1.113; 95% CI 1.038–1.192; p=0.003) and AOPP
(OR=1.022; 95% CI 1.005–1.039; p=0.012) were the
independent predictors of MetS, whereas no association
between NOx and MetS was found. As XOD rose for 1
U/L, XO for 1 U/L, MDA for 1 mmol/L and AOPP for 1
T/L, probability for MetS rose for 1.1%, 1.4%, 11.3% and
Kratak sadr`aj
Uvod: Azot-monoksid (NO) je biomarker oksidativnog stre-
sa i smatra se jednom od klju~nih determinanti energet-
skog metabolizma i vaskularnog tonusa. S obzirom na
opre~ne rezultate dosada{njih studija koje se odnose na
povezanost izme|u produkata azot-monoksida (NOx) i
metaboli~kog sindroma (MetS), cilj ove studije je da se ispi-
ta njihova potencijalna povezanost. Tako|e, cilj je i da se
ispita povezanost izme|u {irokog spektra ostalih biomar -
kera oksidativnog stresa [npr., malondialdehida (MDA),
produkata uznapredovale oksidacije proteina (AOPP),
ksantin oksidoreduktaze (XOD), ksantin oksidaze (XO) i
ksantin dehidrogenaze (XDH)] i MetS.
Metode: Ukupno 109 dobrovoljaca (od kojih je 46,8%
ispunjavalo kriterijume za MetS) je uklju~eno u studiju pre-
seka. Mereni su biohemijski i antropometrijski parametri,
kao i krvni pritisak. Dijagnoza MetS-a je postavljena prema
kriterijumima Me|unarodnog udru`enja za dijabetes.
Rezultati: Multivarijantna logisti~ka regresija je pokazala da
su XOD (OR=1,011; 95% CI 1,002–1,019; p=0,016),
XO (OR=1,014; 95% CI 1,003–1,026; p=0,016), MDA
(OR=1,113; 95% CI 1,038–1,192; p=0,003) i AOPP
(OR=1,022; 95% CI 1,005–1,039; p=0,012) nezavisni
prediktori MetS-a, ali postojanje povezanosti izme|u NOx i
MetS nije utvr|eno. Sa porastom XOD za 1 U/L, XO za 1
U/L, MDA za 1 mmol/L i AOPP za 1 T/L verovatno}a
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Introduction
Metabolic syndrome (MetS) has reached an
alarming rate, parallel with increasing obesity and
type 2 diabetes (DM2), thus representing one of the
major public health concerns (1).
Considering the fact that abdominal obesity is
the key characteristic of MetS (2), it is assumed that
visceral adipose tissue through increased mitochon-
drial oxidation of free fatty acids represents the main
generator of reactive oxygen (ROS) and reactive
nitrogen species (RNS) (3). Indeed, previous studies
confirmed an increase in some of the oxidative stress
biomarkers, as well as a decrease in the antioxidant
defence system in individuals with overweight/obesity
(4, 5). However, it is questionable whether all of these
biomarkers can predict MetS since discrepancies in
the literature exist considering the relationship
between oxidative stress biomarkers and MetS and/or
its components (6–16). 
Nitric oxide (NO) is an oxidative stress biomark-
er which is regarded as one of the key determinants
of energy metabolism and vascular tone (12). It is
generated from L-arginine, and this production is
under the control of enzyme NO synthase (NOS)
(12). NOS exists in three different isoforms (i.e.,
inducible, endothelial and neuronal) which all may
have an impact on the bioavailability of NO in circu-
lation (6, 12). However, it is believed that inducible
NOS has the highest capacity for NO generation
whose expression is increased in response to
inflammation and oxidative stress (12).
Some studies report the decrease in serum NO
(11, 12), while others showed its increase in metabol-
ic disorders (7, 9). In addition, the relationship
between serum nitric oxide products (NOx) and body
fat, rather than between serum NOx and lipid param-
eters was found (8). 
Taking into account controversial results on the
association between NOx (nitrates and nitrites) and
MetS, the aim of the current study was to examine
that potential relationship. Additionally, we aimed to
evaluate a broad spectrum of other oxidative stress
biomarkers [i.e., malondialdehyde (MDA), advanced
oxidation protein products (AOPP), xanthine oxidore-
ductase (XOD), xanthine oxidase (XO) xanthine
dehydrogenase (XDH)] in relation with MetS.
Materials and Methods
Study population
A total of 109 volunteers (62.3% of them
females) were recruited in the research when visiting
the Primary Health Care Center in Podgorica,
Montenegro, for their routine check-up in the period
from October 2015 to May 2016. Clinical examina-
tions and medical history were carried out on the
same day for each participant. 
The diagnosis of MetS was established accord-
ing to the International Diabetes Federation criteria
(17). The examinees that were eligible to enter the
study were divided into two groups: a group without
MetS (n=58) and a group with MetS (n=51). 
Exclusion criteria for all potential participants
were: hsCRP >10 mg/L, acute inflammatory disease,
diabetes mellitus, liver diseases other than steatosis,
kidney diseases, malignant diseases, gout, ethanol
consumption >20 g/day, pregnancy, as well as un -
willingness to participate in the study.
The Ethical Committee of the Primary Health
Care Center in Podgorica, Montenegro approved the
study protocol. All the volunteers provided signed
informed consent, and the research was carried out in
compliance with the Declaration of Helsinki.
Anthropometric and blood pressure 
measurements
Basic anthropometric measurements, as well as
systolic (SBP) and diastolic blood pressure (DBP) were
obtained as described elsewhere (18).
Biochemical analyses
Biochemical analyses were performed after
overnight fasting of at least 8 hours. A cubital venous
blood sample was collected from each participant, as
previously described (18).
Lipid parameters [e.g., total cholesterol (TC),
high density lipoprotein cholesterol (HDL-c), low den-
sity lipoprotein cholesterol (LDL-c), triglycerides
(TG)], glucose, creatinine, uric acid, bilirubin, aspar-
tate aminotransferase (AST), alanine aminotrans-
ferase (ALT) and gamma-glutamyl transferase (GGT),
were measured using standardized enzymatic proce-
2.2%, respectively. Adjusted R2 for the Model was 0.531,
which means that 53.1% of variation in MetS could be
explained with this Model.
Conclusions: Unlike XOD, MDA and AOPP, NOx is not
associated with MetS.
Keywords: inflammation, metabolic syndrome, obesity,
oxidative stress
pojave MetS-a je rasla za 1,1%, 1,4%, 11,3% i 2,2%. Prila -
go|eni R2 za Model iznosio je 0,531, {to ukazuje na to da
~ak 53,1% varijabiliteta u MetS-u mo`e biti obja{njeno
ovim modelom.
Zaklju~ak: Za razliku od XOD, MDA i AOPP, NOx nisu
povezani sa MetS-om.
Klju~ne re~i: inflamacija, metaboli~ki sindrom, gojaz -
nost, oksidativni stres
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dure (Roche Cobas 400, Mannheim, Germany).
HsCRP levels were measured nephelometrically
(Behring Nephelometer Analyzer, BN II, Marburg,
Germany).
Serum MDA level and catalase (CAT), XOD,
and XO activity were measured by spectro photo -
metric assay. Determination of MDA was based on
measuring TBARS by thiobarbituric acid (TBA) test
(19). Determination of XOD and XO in serum was
based on the liberation of uric acid by using xanthine
as a substrate in the presence of NADH (for XOD) or
absence of NADH (for XO) when only molecular oxy-
gen was electron acceptor (20). The XDH activity was
calculated by subtracting XO from XOD activity, and
the results in XOD, XO and XDH, respectively were
expressed in U/L. Deter mination of serum AOPP was
based on spectrophotometric detection of chlo-
ramine-T equivalents. In order to minimise the impact
of storage time of samples, as well as the possible
influence of TG and turbidity of samples, we modified
AOPP assay by precipitating VLDL and LDL in the
plasma (21). 
Serum NOx was determined as follows: nitric
oxide is rapidly converted to nitrite (NO2
-) and nitrate
(NO3
-) in human serum. The measurement of these
anions, commonly named as NOx, is used as an indi-
cator of NO production. In our study, serum NOx levels
were measured as previously described (22) after
chemical reduction of nitrate to nitrite by Cu-coated
cadmium, followed by a colourimetric detection at 540
nm of nitrite as the azo dye product of the Griess reac-
tion. The detection limit of the assay was 2.5 mmol/L.
Catalase (CAT) test was based on the release of
oxygen from hydrogen peroxide (H2O2), by using the
spectrophotometric assay based on the formation of
its stable complex with ammonium molybdate (23).
Statistical analysis
Statistical analysis was performed with SPSS 22
Statistical Package Program for Windows (SPSS Inc,
Chicago, Illinois). The parametric Student t-test and
non-parametric Mann-Whitney U test were used to
test differences between two groups dependent on
the variables distributions. Kolmogorov-Smirnov test
was used for distribution testing. Data are shown as
mean ± standard deviation for normally distributed
continuous variables, as geometrical mean (95% con-
fidence interval) for log-normally distributed variables
(24), and median (interquartile range) for skewed dis-
tributed data. The comparisons of absolute frequen-
cies were performed using Chi-square test for contin-
gency tables. Logistic regression analysis was used to
determine possible associations between MetS and
oxidative stress and inflammation parameters.
Continuous variables which were significantly different
between groups and had not entered the algorithm
for MetS diagnosis were classified as confounders and
applied in multivariate logistic regression models in
order to identify independent predictors of MetS
occurrence. The Hosmer and Lemeshow test was
used to examine whether there was a linear relation-
ship between the confounders and the log odds of the
dependent variable. Results are given as odds ratio
(OR) with 95% confidence intervals (CI). The explained
variation in MetS occurrence was given by Nagel -
kerke R2 value. AP < 0.05 (two-tailed) was consid-
ered statistically significant.
Results
A summary of general demographic characteris-
tics is listed in Table I. Significantly higher BMI and
WC (p<0.001, for both), SBP (p<0.001) and DBP
Table I Basic demographic characteristics of participants without and with metabolic syndrome.
Data are presented as arithmetic mean ± SD and compared by Student t-test. 
* Skewed distributed data are presented as median (interquartile range) and compared by Mann-Whitney test.
** Log – normal distributed data are presented as geometric mean (95% CI) compared by Student t-test. Antihypertensives,
hypolipidemic drugs and smoking habits are given as absolute frequencies and compared by Chi-square test for contingency
tables.
BMI – Body mass index; WC – Waist circumference; SBP – Systolic blood pressure; DBP – Diastolic blood pressure
Participants without MetS Participants with MetS p
N (male/female) 58 (20/38) 51 (21/30) 0.602
Age, years* 55 (40–68) 60 (53–66) 0.266
BMI, kg/m2 ** 26.21 (24.99–27.50) 30.47 (29.40–31.59) <0.001
WC, cm 94.78±13.42 108.45±13.84 <0.001
SBP, mmHg* 130 (136–136) 141 (135–148) <0.001
DBP, mmHg* 77 (70–80) 80 (72–90) 0.010
Antihypertensives (No/Yes) 28/21 30/30 0.582
Hypolipidemic drugs (No/Yes) 48/10 33/18 0.053
Smoking habits, (Smoker/Non-smoker) 46/12 36/15 0.406
(p=0.010) were evident in the group of participants
with MetS. There was no significant difference
between the age of individuals in different groups. No
significant unequal distributions of gender, partici-
pants with smoking habits and therapy usages were
evident between tested groups.
Fasting glucose (p<0.001), HbA1c (p<0.001),
TG (p<0.001), uric acid concentrations (p<0.001),
AST, ALT and GGT activities (p=0.044, p<0.001
and p=0.001, respectively) were significantly higher
in participants with MetS when compared with partic-
ipants without MetS. Also, markers of oxidative stress
such as XO, XOD, MDA and AOPP were evidently
higher in participants with MetS (p=0.044, p=0.012,
p=0.004 and p=0.010, respectively). There was no
difference in NOx levels between participants with
and without MetS (p=0.913). Opposite to this, par-
ticipants with MetS had a lower HDL-c concentration
(p<0.001) (Table II). 
Table III presented results of logistic regression
analysis which was performed in order to examine the
associations of oxidative stress and inflammation
parameters (predictors) and MetS (without MetS
coded 0, with MetS coded 1) as a dependent vari-
able. In the unadjusted model, predictors significantly
associated with MetS occurrence were hsCRP
(OR=1.306; 95% CI 1.052–1.621; p=0.016), XOD
(OR=1.006; 95% CI 1.000–1.012; p=0.047), XO
(OR=1.010; 95% CI 1.001–1.020; p=0.025) and
MDA (OR=1.078; 95% CI 1.022–1.137; p=0.006).
As hsCRP rose for 1 mg/L, XOD for 1 U/L, XO for 1
U/L and MDA for 1 mmol/L probability for MetS rose
for 30.6%, 0.6%, 1.0% and 7.8%, respectively. No
significant associations were determined between
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Table II Clinical characteristics of participants without and with metabolic syndrome.
Participants without MetS Participants with MetS p
Glucose, mmol/L* 5.20 (4.90–5.80) 5.90 (5.40–6.47) <0.001
HbA1c, %** 4.94 (4.80–5.08) 5.40 (5.29–5.55) <0.001
TC, mmol/L 5.52±1.14 5.74±1.33 0.345
HDL-c, mmol/L 1.59±0.42 1.34±0.36 <0.001
LDL-c, mmol/L** 3.18 (2.95–3.43) 3.39 (3.07–3.74) 0.303
TG, mmol/L** 1.29 (1.13–1.46) 1.91 (1.73–2.10) <0.001
hsCRP, mg/L* 1.24 (0.97–1.58) 2.19 (1.77–2.72) 0.001
Bilirubin, mmol/L** 7.46 (6.62–8.41) 7.16 (6.31–8.14) 0.644
Uric acid, mmol/L 264.07±74.77 316.94±68.34 <0.001
Creatinine, mmol/L** 69.31 (65.57–73.27) 73.27 (69.10–77.70) 0.171
eGFR-MDRD, mL/min/1.73 m
2 88.22±20.90 82.69±18.44 0.148
AST, U/L* 19 (17–22) 21 (18–26) 0.044
ALT, U/L* 18 (14–23) 25 (19–35) <0.001
GGT, U/L* 13 (12–18) 19 (14–30) 0.001
XOD, U/L 325.34±61.79 351.60±72.77 0.044
XO, U/L* 127.40 (110.25–142.10) 144.55 (122.50–175.15) 0.012
XDH, U/L 194.48±80.05 199.94±83.10 0.728
MDA, mmol/L 49.74±7.28 54.15±8.25 0.004
AOPP, T/L 67.81 (58.23–118.17) 74.70 (68.17–130.53) 0.010
CAT, U/L 75.06±45.19 66.92±43.54 0.342
NOx, mmol/L 37.69 (32.47–54.69) 40.02 (33.36–49.69) 0.913
Data are presented as arithmetic mean ± SD and compared by Student t-test. 
* Skewed distributed data are presented as median (interquartile range) and compared by Mann-Whitney test.
** Log-normal distributed data are presented as geometric mean (95% CI) compared by Student t-test.
HbA1c-Glycated hemoglobin; TC-Total cholesterol; HDL-c-High density lipoprotein cholesterol; LDL-c-Low density lipoprotein
cholesterol; TG-Triglycerides; hsCRP-High-sensitivity C-reactive protein; eGFRMDRD-Estimated glomerular filtration rate; AST-
Aspartate aminotransferase; ALT-Alanine aminotransferase; GGT-Gamma-glutamyl transferase; XOD-Xanthine oxidoreductase;
XO-Xanthine oxidase; XDH-Xanthine dehydrogenase; MDA- Malondialdehyde; AOPP-Advanced oxidation protein products; CAT-
Catalase; NOx-Nitric oxide products
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XDH, AOPP, CAT, NOx and MetS (Table III). Multi -
variate logistic regression analysis was performed in
order to test if predictors which were significant in
univariate regression analysis confounded with other
clinical parameters which could be independently
associated with MetS occurrence. AST was not
included in the logistic regression model because the
Hosmer-Lemeshow test was significant (p<0.05) for
the Model indicating that there was no linear relation-
ship between the confounders and the log odds of the
dependent variable. Also, BMI, WC, SBP, DBP, lipid
profile parameters, fasting glucose and HbA1c were
excluded from the logistic regression analysis because
they were used in MetS diagnosis algorithm. Multi -
variate logistic regression analysis showed that XOD
(OR=1.011; 95% CI 1.002–1.019; p=0.016), XO
(OR=1.014; 95% CI 1.003–1.026; p=0.016), MDA
(OR=1.113; 95% CI 1.038–1.192; p=0.003) and
AOPP (OR=1.022; 95% CI 1.005–1.039; p=0.012)
were the independent predictors of MetS. As XOD
rose for 1 U/L, XO for 1 U/L, MDA for 1 mmol/L and
AOPP for 1 T/L, probability for MetS rose for 1.1%,
1.4%, 11.3% and 2.2%, respectively. HsCRP lost its
independent prediction on MetS occurrence (OR=
1.199; 95% CI 0.922–1.560; p=0.175) in multivari-
ate logistic regression analysis. Adjusted R2 for the
Model was 0.531, which means that 53.1% of the
variation in MetS could be explained with this Model
(Table III). Observed post-hoc power of the study
based on multiple regression analysis for 8 predictors,
probability level 0.05 and R2= 0.531 was 0.99 (25).
Discussion
The findings of the current study showed an
independent association of different oxidative stress
biomarkers with MetS (Table III). However, NOx showed
no association with MetS.
In our study, we have confirmed that both, MDA
and AOPP were reliable predictors of MetS in non-
diabetic participants, showing that proteins are equal-
ly targeted by ROS as lipids. Furthermore, we have
also shown the increase in XOD and XO in individuals
with MetS, and both of these biomarkers were shown
to be the independent predictors of MetS (Table III). 
Previous studies that examined the impact of dif-
ferent oxidative stress biomarkers on MetS status lack
consistency (6–16). Venturini et al. (13) did not find
the increase in MDA (i.e., a primary biomarker of lipid
peroxidation) in individuals with obesity, but did in
MetS, thus suggesting that a cluster of cardio -
metabolic risks, rather than obesity per se, could lead
to the apparent increase in MDA level. On the other
hand, Abdilla et al. (14) found no relationship between
MDA and each MetS component, but only a weak
association with BMI.
Regarding AOPP as a marker of oxidative dam-
age of proteins, previous studies were consistent and
showed its increase in MetS (15, 26). Moreover,
Ventu rini et al. (26) reported the superiority of AOPP
over lipid peroxidation biomarkers in relation to MetS
components. 
To our knowledge, only one study examined the
XO activity in relation with MetS, so far. Although the
latter study included a smaller sample size of exami-
nees than ours, we have confirmed their results, thus
Table III Odds ratios (OR) after univariate and multivariate
logistic regression analysis for clinical parameters predicting
metabolic syndrome.
Model: HsCRP, uric acid, ALT, GGT, XOD, XO, MDA and
AOPP
hsCRP – High-sensitivity C-reactive protein; XOD – Xanthine
oxidoreductase; XO – Xanthine oxidase; XDH – Xanthine
dehydrogenase; MDA – Malondialdehyde; AOPP –
Advanced oxidation protein products; CAT – Catalase; NOx
– Nitric oxide products
Predictors Unadjusted OR (95% CI) p
Nagelkerke 
R2
hsCRP, mg/L 1.306(1.052–1.621) 0.016 0.080
XOD, U/L 1.006(1.000–1.012) 0.047 0.050
XDH, U/L 1.001(0.996–1.006) 0.725 0.002
XO, U/L 1.010(1.001–1.020) 0.025 0.068
MDA, mmol/L 1.078(1.022–1.137) 0.006 0.102
AOPP, T/L 1.009(0.998–1.020) 0.095 0.034
CAT, U/L 0.996(0.987–1.004) 0.340 0.011
NOx, mmol/L 1.002(0.985–1.019) 0.843 0
Model Adjusted OR (95% CI) P
Nagelkerke
R2
hsCRP, mg/L 1.199(0.922–1.560) 0.175
0.531 
(for model)
XOD, U/L 1.011(1.002–1.019) 0.016
XO, U/L 1.014(1.003–1.026) 0.016
MDA, mmol/L 1.113(1.038–1.192) 0.003
AOPP, T/L 1.022(1.005–1.039) 0.012
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showing an increase in XO activity in MetS (27). This
enzyme can contribute to the controlling of vascular
tone and endothelial function by modulating the
bioavailability of endothelial NO. Moreover, XO is
involved in adipogenesis, as well as in the production
of uric acid, which all can explain the role of XO in
the pathogenesis of cardiometabolic diseases (28).
However, the most contradictory results were
shown regarding NOx. While one group of authors
reported the decrease of NOx in the state of obesity
and diabetes (11, 12), the other claimed the oppo-
site, showing its increase (7, 9) in individuals with
MetS and diabetes. Our results are similar to the third
group of researchers who found a non-significant
increase of NOx production in obesity, diabetes and
MetS (29, 30). Namely, Caimi et al. (30) found no
difference between diabetic and non-diabetic individ-
uals with MetS. On the other hand, Ueyama et al. (6)
found the inverse correlation between NOx and HDL-
c only in males, but not in females. However, no rela-
tionship between serum NOx levels and other MetS
components, such as high BMI, high TG, or hyper -
tension was reported (6). Furthermore, Chedraui et
al. (7) also found the inverse correlation between
NOx and HDL-c, but a strong positive correlation with
TG in the cohort of examined postmenopausal
women.
Different populations of studied groups and
their different sample-size, may at least in part explain
these discrepancies. Also, NOS, the enzyme respon-
sible for NO production, exists in three isoforms, but
it is suggested that inducible NOS, rather than
endothelial or neuronal NOS, is the main isoform
whose expression is increased in oxidant and inflam-
matory states, such as obesity (31). However, the
high sensitivity of NO to ROS results in generating
other reactive species, which may also influence the
bioavailability of NOx (31). In addition, a problem
concerning distinguishing between NO production
from constitutive or inducible NOS isoforms, may also
partly explain discrepancies between studies.
The cross-sectional design is the limitation of
our study which does not allow us to establish the
causal link between oxidative stress and MetS.
However, our study has some advantages, since we
have included a broad spectrum of oxidative stress
biomarkers in relation with MetS. In addition, only
one study, but with a smaller sample size than ours,
examined the role of XO in MetS. Thus, new studies
with longitudinal design are needed to confirm our
results.
Conclusion
The finding of the current study revealed an
independent relationship of different oxidative stress
biomarkers with MetS occurrence. However, no asso-
ciation between NOx and MetS was found. 
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